Current status of immunotherapies for treating pancreatic cancer
AA Wu, E Jaffee, V Lee - Current oncology reports, 2019 - Springer
AA Wu, E Jaffee, V Lee
Current oncology reports, 2019•SpringerAbstract Purpose of Review Despite all efforts, pancreatic ductal adenocarcinoma (PDAC)
remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate
of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings We
discuss the advances and difficulties in using immunotherapy and developing
immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific
immunotherapy has been propelled by advances in multiple areas, such as next-generation …
remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate
of 7%. Innovative paradigms for treating PDAC are urgently needed. Recent Findings We
discuss the advances and difficulties in using immunotherapy and developing
immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific
immunotherapy has been propelled by advances in multiple areas, such as next-generation …
Purpose of Review
Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed.
Recent Findings
We discuss the advances and difficulties in using immunotherapy and developing immunotherapeutic vaccines for PDAC. Current excitement about antigen-specific immunotherapy has been propelled by advances in multiple areas, such as next-generation sequencing to identify neoantigens and manufacturing to produce immunotherapeutic vaccines. Antigen-specific immunotherapy is being actively explored in clinical trials.
Summary
As the field of immunotherapy matures and as our understanding of the complex interactions between tumor and host develops, we hope to identify new methods for treating and managing PDAC.
Springer